Atherio Creates a Support Team for "Light The Night": Rallying for a Cure with The Leukemia & Lymphoma Society
Jacksonville, FL (PRWEB) October 10, 2013 -- Atherio, one of Florida’s fastest growing companies specializing in enterprise technology and business services, is lending their support to the Leukemia & Lymphoma Society by helping raise awareness, money, and local event participation to eradicate leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
Team Atherio will walk in the Light The Night Walk on Thursday November 7, 2013 at 5:30pm EST, at The Jacksonville Landing in Jacksonville, Florida. For more than 60 years, The Leukemia & Lymphoma Society (LLS) has been solely focused on helping people with blood cancers.
“Our dedication to The Leukemia & Lymphoma Society goes beyond personal commitment. Collectively, the Atherio team is committed to investing our time in improving society, and making a difference in the communities we live in. It is hard to ignore the positive impact made by this worthy cause and we are honored to participate in this year’s walk,” said Jason Cory, CEO and Leader of Team Atherio.
Light The Night Walk is the largest cancer fundraising evening walk in the country, attracting more than 250,000 participants each year. Fundraising efforts like Light The Night, make LLS the single largest nonprofit contributor to blood cancer research. LLS is able to provide more than $44 million in financial aid and co-pay assistance to cancer patients annually.
Critical treatment innovations have originated through blood cancer research, including radiation, chemotherapy, stem cell transplantation, and new-targeted therapies. Significant progress continues to be made to improve the lives of people living with blood cancer.
Nearly 50% of all FDA-approved cancer drugs during the past decade were for blood cancer:
• Five of those drugs have been approved for use in additional cancer indications; clinical trials are underway for the other 14 FDA-approved treatments for additional indications.
• Survival rates for children with lymphocytic leukemia (the most common childhood cancer) have risen from 3% to 90% since the 1960s.
• Hodgkin lymphoma patient survival rates have doubled (now 88%) since the 1960s.
To find out more about supporting Team Atherio or participating in Light The Night Walk visit http://pages.lightthenight.org/ncfl/Jacksonv13/teamatherio#Welcome-to-our-Teams-Homepage
About Us
Atherio, Inc.
Atherio is a leading global technology services company providing end-to-end technology enabled business solutions to the enterprise. Atherio is differentiated in the market through their “maniacal focus on client satisfaction”, market driven service offerings and an unsurpassed knowledge of the industries & vertical markets they serve. http://www.Atherio.com
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit http://www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.
Trademarks
Atherio, Red River Solutions, Dr.Healthcheck and NVISH are registered trademarks of Atherio, Inc. and/or its affiliates. Other names may be trademarks of their respective owners.
Jason M. Cory- Chairman and CEO, Atherio, http://www.Atherio.com, +1 904-791-8888 100, [email protected]
Share this article